Wealthspire Advisors (New York)’s Annovis Bio ANVS Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.2K	Hold	20,000	–	–	﹤0.01%	1260
2026 Q1	$44.6K	Hold	20,000	–	–	﹤0.01%	909
2025 Q4	$69.2K	Buy	20,000 +10,000	+100%	+$30.1K	﹤0.01%	1013
2025 Q3	$20.7K	Hold	10,000	–	–	﹤0.01%	1668
2025 Q2	$21.7K	Sell	10,000 -50	-0.5%	-$99	﹤0.01%	842
2025 Q1	$15.1K	Hold	10,050	–	–	﹤0.01%	784
2024 Q4	$50.6K	Buy	10,050 +50	+0.5%	+$362	﹤0.01%	774
2024 Q3	$80.6K	Hold	10,000	–	–	﹤0.01%	729
2024 Q2	$57.6K	Hold	10,000	–	–	﹤0.01%	648
2024 Q1	$119K	Sell	10,000 -990	-9%	-$10.8K	﹤0.01%	622
2023 Q4	$206K	Buy	10,990 +990	+10%	+$8.78K	﹤0.01%	613
2023 Q3	$94.9K	Hold	10,000	–	–	﹤0.01%	580
2023 Q2	$143K	Hold	10,000	–	–	﹤0.01%	542
2023 Q1	$154K	Buy	+10,000	New	+$161K	﹤0.01%	510
2021 Q4	–	Sell	-7,500	Closed	-$238K	–	540
2021 Q3	$238K	Buy	7,500 +2,500	+50%	+$144K	﹤0.01%	505
2021 Q2	$428K	Sell	5,000 -5,000	-50%	-$231K	0.01%	240
2021 Q1	$279K	Buy	+10,000	New	+$214K	0.01%	572

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wealthspire Advisors (New York)'s ANVS Position: Q2 2026 in Review

Wealthspire Advisors (New York) held its Annovis Bio (ANVS) position steady in Q2 2026 at 20,000 shares worth $37.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Wealthspire Advisors (New York) first reported a position in ANVS in Q1 2021 and has held it in 17 quarters since. The position peaked at $428K in Q2 2021. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

Wealthspire Advisors (New York) held 20,000 shares of Annovis Bio worth $37.2K as of Q2 2026.
Wealthspire Advisors (New York) left its Annovis Bio share count unchanged in Q2 2026.
Annovis Bio made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1260 holding.
Wealthspire Advisors (New York) first reported a position in Annovis Bio in Q1 2021 and has held it in 17 quarters since.
Wealthspire Advisors (New York)'s Annovis Bio position peaked at $428K in Q2 2021.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.